Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Suspended 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Carcinoma, Non-Small-Cell Lung 55Carcinoma, Hepatocellular 54Lung Neoplasms 32Small Cell Lung Carcinoma 27Neoplasms 25Breast Neoplasms 20Colorectal Neoplasms 18Melanoma 15Triple Negative Breast Neoplasms 14Urinary Bladder Neoplasms 13Carcinoma, Transitional Cell 13Neoplasm Metastasis 12Carcinoma, Renal Cell 12Squamous Cell Carcinoma of Head and Neck 10Prostatic Neoplasms 9Uterine Cervical Neoplasms 8Stomach Neoplasms 8Glioblastoma 8Endometrial Neoplasms 7Ovarian Neoplasms 6Head and Neck Neoplasms 6Sarcoma 5Pancreatic Neoplasms 5Carcinoma, Neuroendocrine 5Carcinoma, Merkel Cell 5Liver Neoplasms 4Kidney Neoplasms 4Extensive Stage Lung Small Cell Carcinoma 4Carcinoma 4Brain Neoplasms 4

Interventions

Cisplatin 32Radiotherapy, Intensity-Modulated 21Magnetic Resonance Spectroscopy 21Radiotherapy 16Specimen Handling 15Radiation 14Carboplatin 14pembrolizumab 13Platinum 121,2-diaminocyclohexaneplatinum II citrate 11Paclitaxel 8Chemoradiotherapy 7Biopsy 7Taxes 6Surveys and Questionnaires 6Cetuximab 6Nivolumab 5Surgical Procedures, Operative 4Observation 4Fluorodeoxyglucose F18 4Drug Therapy 4Docetaxel 4durvalumab 3(225)Ac-DOTA-c(RGDyK) 3toripalimab 2cemiplimab 2atezolizumab 2aldesleukin 2X-Rays 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Oropharyngeal Neoplasms × atezolizumab × 1 year × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06254911 2026-01-27

Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma

Emory University

Phase 2 Suspended
20 enrolled
Head & Neck

Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡